Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

This Phase II study is testing a combination of two drugs — golidocitinib (a JAK inhibitor) and benmelstobart (an immunotherapy) — in people with a rare and aggressive type of blood cancer called extranodal NK/T cell lymphoma (ENKTL) that has returned or stopped responding to previous treatment. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of extranodal NK/T cell lymphoma (ENKTL) - Your cancer has not responded to or has relapsed after at least one prior treatment regimen containing asparaginase - You have at least one measurable lesion - You are in adequate overall health with sufficient organ function - Your expected survival is at least 3 months **You may NOT be eligible if...** - Your lymphoma has transformed into leukemia or has spread to the central nervous system - You have a condition called hemophagocytic lymphohistiocytosis (HLH) - You have previously been treated with a JAK inhibitor - You have contraindications to any of the study drugs Talk to your doctor to see if this trial is right for you.